NPPB and pulmonary arterial hypertension: These risk assessment tools have been found to effectively predict one-year survival and have been validated in patients with PAH based on several disease-specific characteristics, such as six-minute walk distance (6MWD), B-type natriuretic peptide (BNP), functional class (FC), and pulmonary hemodynamics.